Compare Stocks: BCYC, ORIC, SVRA, and MLTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.70 +0.7%	$3.81	$3.33 ▼ $7.83	$258.61M	1.59	420,672 shs	174,446 shs
MLTX MoonLake Immunotherapeutics	$11.51 -1.6%	$12.36	$9.46 ▼ $23.29	$978.34M	1.14	1.53 million shs	881,345 shs
ORIC Oric Pharmaceuticals	$9.37 -2.3%	$12.28	$7.23 ▼ $14.68	$976.90M	1.23	1.74 million shs	2.24 million shs
SVRA Savara	$4.63 -2.6%	$5.04	$3.86 ▼ $7.01	$944.09M	0.32	1.75 million shs	2.82 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+1.38%	-2.91%	+8.58%	-7.56%	-49.45%
MLTX MoonLake Immunotherapeutics	+2.01%	-1.93%	+2.54%	-33.33%	+14.71%
ORIC Oric Pharmaceuticals	+5.73%	+6.56%	-21.39%	-25.83%	-24.43%
SVRA Savara	+0.42%	-2.26%	-1.25%	-13.79%	+11.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.70 +0.7%	$3.81	$3.33 ▼ $7.83	$258.61M	1.59	420,672 shs	174,446 shs
MLTX MoonLake Immunotherapeutics	$11.51 -1.6%	$12.36	$9.46 ▼ $23.29	$978.34M	1.14	1.53 million shs	881,345 shs
ORIC Oric Pharmaceuticals	$9.37 -2.3%	$12.28	$7.23 ▼ $14.68	$976.90M	1.23	1.74 million shs	2.24 million shs
SVRA Savara	$4.63 -2.6%	$5.04	$3.86 ▼ $7.01	$944.09M	0.32	1.75 million shs	2.82 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+1.38%	-2.91%	+8.58%	-7.56%	-49.45%
MLTX MoonLake Immunotherapeutics	+2.01%	-1.93%	+2.54%	-33.33%	+14.71%
ORIC Oric Pharmaceuticals	+5.73%	+6.56%	-21.39%	-25.83%	-24.43%
SVRA Savara	+0.42%	-2.26%	-1.25%	-13.79%	+11.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.30	Hold	$13.57	267.29% Upside
MLTX MoonLake Immunotherapeutics	2.54	Moderate Buy	$28.50	147.57% Upside
ORIC Oric Pharmaceuticals	2.81	Moderate Buy	$21.25	126.76% Upside
SVRA Savara	2.75	Moderate Buy	$10.25	121.62% Upside

Current Analyst Ratings Breakdown

Latest BCYC, ORIC, SVRA, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/29/2026	BCYC Bicycle Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
10/28/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$26.00
10/27/2026	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$17.00 ➝ $14.00
10/26/2026	ORIC Oric Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$14.00 ➝ $18.00
10/15/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	BCYC Bicycle Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/14/2026	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$23.00 ➝ $26.00
10/7/2026	SVRA Savara	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$10.00
10/7/2026	SVRA Savara	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/7/2026	SVRA Savara	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$72.86M	3.55	N/A	N/A	$7.22 per share	0.51
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$218.96M	-$2.03	N/A	N/A	N/A	-169.75%	-26.02%	-22.30%	N/A
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest BCYC, ORIC, SVRA, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ORIC Oric Pharmaceuticals	-$0.3836	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	SVRA Savara	-$0.1633	N/A	N/A	N/A	$0.50 million	N/A
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.77	-$0.93	-$0.16	-$0.93	N/A	N/A
10/29/2026	Q3 2026	BCYC Bicycle Therapeutics	-$0.3990	-$0.15	+$0.2490	-$0.15	$12.22 million	$34.06 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	12.09	12.09
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
MLTX MoonLake Immunotherapeutics	93.85%
ORIC Oric Pharmaceuticals	95.05%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.00%
MLTX MoonLake Immunotherapeutics	10.40%
ORIC Oric Pharmaceuticals	5.70%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

BCYC, ORIC, SVRA, and MLTX Headlines

Recent News About These Companies

Savara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Finance

November 4 at 9:17 AM | finance.yahoo.com

Savara (SVRA) Expected to Release Earnings on Wednesday

November 4 at 8:40 AM | marketbeat.com

Savara Inc. (NASDAQ:SVRA) Stock Short Interest Report for October

November 2 at 6:01 AM | americanbankingnews.com

Savara Inc. (NASDAQ:SVRA) Sees Significant Drop in Short Interest

November 2 at 5:59 AM | marketbeat.com

Savara (NASDAQ:SVRA) Stock Price Down 6.5% - Should You Sell?

October 23, 2026 | marketbeat.com

Savara Inc. Presents New Data Showing Molgramostim Inhalation Solution Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis Patients with Mild Diffusion Impairment

October 22, 2026 | marketscreener.comM

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment

October 21, 2026 | businesswire.com

Savara presents CHEST data before the FDA decision for Savara stock

October 20, 2026 | ad-hoc-news.deA

Savara schedules CHEST 2026 presentations for Savara stock

October 18, 2026 | ad-hoc-news.deA

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

October 13, 2026 | finance.yahoo.com

Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts

October 13, 2026 | marketbeat.com

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis ...

October 12, 2026 | joplinglobe.comJ

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

October 12, 2026 | businesswire.com

JPMorgan starts Savara coverage with USD 12 target for Savara stock

October 8, 2026 | ad-hoc-news.deA

Savara stock gets USD 12 JPMorgan target before FDA date

October 8, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

October 7, 2026 | marketbeat.com

JPMorgan Initiates Savara at Overweight With $12 Price Target

October 7, 2026 | marketscreener.comM

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

October 7, 2026 | streetinsider.com

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

October 7, 2026 | marketbeat.com

Savara stock fell 4.66 percent ahead of the November FDA decision

October 4, 2026 | ad-hoc-news.deA

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?

September 24, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BCYC, ORIC, SVRA, and MLTX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$3.70 +0.03 (+0.68%)

As of 03:45 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.51 -0.19 (-1.61%)

As of 03:46 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Oric Pharmaceuticals NASDAQ:ORIC

$9.37 -0.22 (-2.28%)

As of 03:46 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Savara NASDAQ:SVRA

$4.62 -0.13 (-2.63%)

As of 03:46 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, ORIC, SVRA, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, ORIC, SVRA, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, ORIC, SVRA, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCYC, ORIC, SVRA, and MLTX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

MoonLake Immunotherapeutics NASDAQ:MLTX

Oric Pharmaceuticals NASDAQ:ORIC

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, ORIC, SVRA, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, ORIC, SVRA, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, ORIC, SVRA, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCYC, ORIC, SVRA, and MLTX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

MoonLake Immunotherapeutics NASDAQ:MLTX

Oric Pharmaceuticals NASDAQ:ORIC

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools